Home » Newsletters » BioWorld Science

BioWorld Science

April 29, 2004

View Archived Issues

A study reveals a reduction in the incidence and mortality of stroke in Finland

Protein tyrosine phosphatase 1B inhibitors from Roche

New data on the efficacy of pegylated interferon alfa-2b in viral hepatitis

Novel proteasome inhibitor ER807446 demonstrates antitumor activity especially against large tumors

Inhibition of dopamine transport: a novel treatment for obesity

Antiatherosclerotic action of aminobisphosphonates

NF-kappaB inhibitor DHMEQ as treatment option for advanced urological cancer

Novel p38alpha MAP kinase inhibitors under study at Scios

Selective antagonist action on food intake not only mediated by NPY Y5 receptor

Two novel series of CDK inhibitors presented by Schering-Plough and Pharmacopeia

Agents combining antibacterial and beta-lactamase activity identified at Aventis Pharma

Cellular Genomics patent covers new protein kinase modulators

New GlyT-2 inhibitors in early development at NPS Allelix

NPS Allelix presents new GlyT-1 inhibitors and their use in schizophrenia and cognition disorders

Novartis claims new alpha7 nAChR agonists and their use

Highlights from the 3rd Annual Global Biotech Forum for Investing & Partnering: Viral Therapeutics

R&D highlights from the 3rd Annual Global Biotech Forum for Investing & Partnering: Transave

R&D highlights from the 3rd Annual Global Biotech Forum for Investing & Partnering: Sirenade

Allergan to withdraw PEP-005 INDs, resubmission planned

Second phase III trial for regadenoson

SARS antibody sent to Sinovac for preclinical testing

GA-GCB enters clinical trial for Gaucher's disease

AlzheimAlert PMA accepted for filing

MedImmune to reacquire rights to FluMist and CAIV-T from Wyeth

EntreMed completes phase I trial with reformulated Panzem

Priority Healthcare becomes preferred specialty pharmacy provider of Apokyn

Celmed BioSciences sells neurology assets and technology platform

Fast track status for DB-289 for African sleeping sickness

New indication and strength approved for Hectorol

Nanogen completes acquisition of SynX

New positive opinion for Herceptin plus Taxotere in E.U.

PARP activation shown to be involved in diabetic neuropathy in mice and rats

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...